Sarepta Therapeutics Inc Clinical Update: Study SRP-9001-103: 12-Week Expression and Safety Data Using Commercially Representative Material - Call Transcript
Good morning, and welcome to the Sarepta Therapeutics conference call and webcast for the clinical update for study SRP-9001-103 12-Week Expression and Safety Data Using Commercially Representative Material. (Operator Instructions) As a reminder, today's program is being recorded.
Now I will turn the call over to Mr. Doug Ingram, President and CEO, for opening remarks.
Thank you. Good morning, and thank you for joining us for the report out from our 11 patient cohort update, our study to characterize our DMD gene therapy 9001 using our commercial process material.
Now before I turn the call over to Dr. Rodino-Klapac, let me contextualize these results. I have said before, and I will repeat it here. It is difficult to overstate the importance of this data. Indeed, these results are one of the most significant ones yet in Sarepta's history and with the benefit of hindsight, I believe, may be among the most seminal moments in the treatment of Duchenne muscular
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |